Multicellular living organisms and unmodified parts thereof and – Nonhuman animal – Transgenic nonhuman animal
Reexamination Certificate
2003-08-08
2008-09-02
Sullivan, Daniel M (Department: 1636)
Multicellular living organisms and unmodified parts thereof and
Nonhuman animal
Transgenic nonhuman animal
C800S003000, C800S008000, C800S009000, C800S013000
Reexamination Certificate
active
07420100
ABSTRACT:
The present invention relates to cardiac hypertrophy. More particularly, the present invention defines the molecular events linking calcium stimulation to cardiac hypertrophy. More specifically, the present invention shows that Ca2+stimulation of the hypertrophic response is mediated through an HDAC 4 and 5 interaction with MEF2, and that phosphorylation of HDACs results in loss of HDAC-mediated repression of MEF2 hypertrophic action. Thus, the present invention provides methods and compositions of treating cardiac hypertrophy, as well as methods and compositions for identifying subjects at risk for cardiac hypertrophy. Further provided are methods for the detection of compounds having therapeutic activity toward cardiac hypertrophy.
REFERENCES:
patent: 4367110 (1983-01-01), Yoshikawa
patent: 4452901 (1984-06-01), Gordon et al.
patent: 4668621 (1987-05-01), Doellgast
patent: 4873191 (1989-10-01), Wagner et al.
patent: 5252479 (1993-10-01), Srivastava
patent: 5359046 (1994-10-01), Capon et al.
patent: 5672344 (1997-09-01), Kelley et al.
patent: 5708158 (1998-01-01), Hoey
patent: 5942435 (1999-08-01), Wheeler
patent: WO 84/03564 (1984-09-01), None
patent: WO 94/05776 (1994-03-01), None
patent: WO 99/19471 (1999-04-01), None
patent: WO 01/14581 (2001-03-01), None
Swiss-Prot Online Database entry Q9Z2V6, downloaded Aug. 18, 2005.
Campbell and Wilmut (1997) Totipotency or Multipotentiality of Cultured Cells: Applications and Progress. Teratology 47:63-72.
Wall (1996) Transgenic Livestock: Progress adn Prospects for teh Future. Theriogenology 45:57-68.
Chang et al. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development, Mol Cell Biol. Oct. 2004;24(19):8467-76.
Gerlai R. Gene-targeting studies of mammalian behavior: is it the mutation or the background genotype? Trends Neurosci. May 1996;19(5):177-81.
Le Mouellic et al. Targeted replacement of the homeobox gene Hox-3.1 by theEscherichia colilacZ in mouse chimeric embryos. Proc Natl Acad Sci U S A. Jun. 1990;87(12):4712-6.
Doetschman T. Interpretation of phenotype in genetically engineered mice. Lab Anim Sci. Apr. 1999;49(2):137-43.
Sigmund CD. Viewpoint: are studies in genetically altered mice out of control? Arterioscler Thromb Vasc Biol. Jun. 2000;20(6):1425-9.
Verdel et al. Identification of a new family of higher eukaryotic histone deacetylases. Coordinate expression of differentiation-dependent chromatin modifiers.J Biol Chem. Jan. 22, 1999;274(4):2440-5.
Vega et al. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell. Nov. 12, 2004;119(4):555-66.
Backs et al. (2006) J. Clin. Invest. 116:1853-1864.
Swiss-Prot entry P12813, http://ca.expasy.org/uniprot/Q9UBM7, downloaded Aug. 28, 2007.
Bour et al., “Drosophila MEF2, a transcription factor that is essential for myogenesis,”Genes and Dev., 9:730-741, 1995.
Brand, “Myocyte enhancer factor 2 (MEF2),”Int. J. Biochem. Cell Biol., 29(12):1467-1470; 1997.
Bustamante et al., “Stretch-activated channels in heart cells: relevance to cardiac hypertrophy,”J. Cardiovasc. Pharmacol, 17 (Supp 2):S110-113, 1991.
Chien et al., “Transcriptional regulation during cardiac growth and development,”Ann. Rev. Physiol.55, 77-95, 1993.
Clarke et al., “Epidermal Growth Factor Induction of the c-jun Promoter by a Rac Pathway,”Mol. Cell Biol., 18(2):1065-1073, 1998.
Coso et al., “Signaling from G Protein-coupled Receptors to the c-jun promoter Involves the MEF2 Transcription Factor,”J. Biol. Chem., 272(33):20691-20697, 1997.
Dubensky et al., “Direct transfection of viral and plasmid DNA into the liver or spleen of mice,”Proc. Nat'l Acad. Sci. USA, 81:7529-7533, 1984.
Edmondson et al., “MEF2 gene expression marks the cardiac and skeletal muscle lineages during mouse embryogenesis,”Development, 120:1251-1263, 1994.
Fischele et al., “A new family of human histone deacetylases related toSaccharomyces cerevisiaeHDA1p,”J. Biol. Chem., 274(17):11713-11720, 1999.
Grozinger et al., “Three proteins define a class of human histone deacetylases related to yeast Hda1p,”Proc. Nat'l. Acad. Sci., 96:4868-4873, 1999.
Gruver et al., “Targeted developmental overexpression of calmodulin induces proliferative and hypertrophic growth of cardiomyocytes in transgenic mice,”Endocrinology, 133(1):376-388, 1993.
Han et al., “Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation,”Nature, 386:296-299, 1997.
Hasegawa et al., “Cis-acting sequences that mediate induction of the -myosin heavy chain gene expression during left ventricular hypertrophy due to aortic constriction,”Circulation, 96(11):3943-3953, 1997.
Herzig et al., “Angiotensin II type 1a receptor gene expression in the heart: AP-1 and GATA-4 mediate the response to pressure overload,”Proc. Nat'l Acad. Sci. USA, 94:7543-7548, 1997.
Hoch et al., “Identification and expression of δ-Isoforms of the multifunctional Ca2+/Calmodulin-dependent protein kinase in failing and nonfailing human myocardium,”Circulation Res., 84:713-721, 1999.
Hongo et al., “Effect of stretch on contraction and the Ca2+transient in ferret ventricular muscles during hypoxia and acidosis,”Am. J. Physiol., 269:C690-C697, 1995.
Kao et al., “Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression,”Genes Dev., 14:55-66, 2000.
Kariya et al., “An enhancer core element mediates stimulation of the rat-myosin heavy chain promoter by an α1-adrenergic agonist and activated β-protein kinase C in hypertrophy of cardiac myocytes,”J. Biol. Chem., 269(5):3775-3782, 1994.
Karliner et al., “Effects of pertussis toxin on α1-agonist-mediated phosphatidylinositide turnover and myocardial cell hypertrophy in neonatal rat ventricular myocytes,”Experientia., 46:81-84, 1990.
Kato et al., “BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C,”EMBO J., 16(23):7054-7066, 1997.
Komuro and Yazaky, “Control of cardiac gene expression of mechanical stress,”Annu. Rev. Physiol., 55:55-75, 1993.
Kovacic-Milivojevic et al., “Selective regulation of the atrial natriuretic peptide gene by individual components of the activator protein-1 complex,”Endocrin, 137(3):1108-1117, 1996.
Le Guennec et al., “Stretch induced increase of resting intracellular calcium concentration in single guinea-pig ventricular myocytes,”Exp. Physiol., 76:975-978, 1991.
Lee et al., “Myocyte-Specific Enhancer Factor 2 and Thyroid Hormone Receptor Associate and Synergistically Activate the α-Cardiac Myosin Heavy-Chain Gene,”Mol. Cell Biol., 17(5):2745-2755, 1997.
Lemercier et al., “mHDA1/HDAC5 histone deacetylase interacts with and represses MEF2A transcriptional activity,”J. Biol. Chem., 275(20):15594-15599, 2000.
Lilly et al., “Requirement of MADS domain transcription factor D-MEF2 for muscle formation inDrosophila,” Science, 267:688-693, 1995.
Lin et al., “Control of cardiac morphogenesis and myogenesis by transcription factor MEF2C,”Science, 276:1404-1407, 1997.
Liu et al., “Cyclosporin A-sensitive induction of the Epstein-Barr virus lytic switch is mediated via a novel pathway involving a MEF2 family member,”EMBO J., 16(1):143-153, 1997.
Lu et al., “Regulation of skeletal myogenesis by association of the MEF2 transcriptional factor with class II histone deacetylases,”Mol Cell, 6:233-244, 2000.
Lu et al., “Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases,”PNAS, 97(8):4070-4075, 2000.
Marban et al., “Intracellular free calcium concentration measured with19F NMR spectroscopy in intact ferret hearts,”Proc. Nat'l Acad. Sci.
Lu Jianrong
McKinsey Timothy
Olson Eric N.
Board of Regents , The University of Texas System
Fulbright & Jaworski
Sullivan Daniel M
LandOfFree
Methods and compositions relating to HDAC 4 and 5 regulation... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions relating to HDAC 4 and 5 regulation..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions relating to HDAC 4 and 5 regulation... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3979156